Study details
Enrolling now
A Study of NN3201 for Advanced Cancer
Novelty Nobility, Inc.
NCT IDNCT06805825ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
67
Study length
about 2.9 years
Ages
18+
Locations
5 sites in MI, OH, OR +2
About this study
Researchers are testing a new drug called NN3201 in people with advanced or metastatic solid tumors that have c-Kit. The goal is to see if the drug is safe and well-tolerated. The trial will involve two phases: a dose escalation phase to determine the maximum tolerated dose, followed by an expansion phase to assess the drug's effectiveness.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take NN3201
PhasePhase 1
Primary goalIncidence of Adverse Events
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Incidence of Adverse Events:
Secondary: Pharmacokinetics (PK) of NN3201
Body systems
Oncology, Gastroenterology